Literature DB >> 11698466

NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts.

C Smith1, E Andreakos, J B Crawley, F M Brennan, M Feldmann, B M Foxwell.   

Abstract

The transcription factor NF-kappaB is of major importance in the biology of pro-inflammatory cytokines, such as TNF-alpha and IL-1alpha, and thereby is intimately involved in the process of inflammation. Understanding the mechanisms by which NF-kappaB is activated in response to inflammatory stimuli has become a major goal of inflammation research. The discovery of NF-kappaB-inducing kinase (NIK) as a TNFR-associated factor-interacting enzyme and a potential activator of the IkappaBalpha-kinase complex appeared to have identified an important element of the NF-kappaB activation pathway, a view that was supported by several subsequent studies. However, recent experiments in the alymphoplasia (aly/aly) mouse, which has missense point mutation (G885R) in NIK, has challenged that view. The reasons for the discrepancy between the different studies is unclear and could be due to multiple factors, such as cell type, species of cell, or primary vs transformed cell lines. One system that has not been investigated is primary human cells. Using an adenoviral vector encoding kinase-deficient NIK, we have investigated the role of NIK in LPS, IL-1, TNF-alpha, and lymphotoxin (LT) betaR signaling in primary human cells and TNF-alpha expression from rheumatoid tissue. These data show that, in the primary systems tested, NIK has a restricted role in LTbetaR signaling and is not required by the other stimuli tested. Also, there is no apparent role for NIK in the process of TNF-alpha production in human rheumatoid arthritis. These data also highlight the potential problems in extrapolating the function of signaling pathways between primary and transfected cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698466     DOI: 10.4049/jimmunol.167.10.5895

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?

Authors:  M Feldmann; E Andreakos; C Smith; J Bondeson; S Yoshimura; S Kiriakidis; C Monaco; C Gasparini; S Sacre; A Lundberg; E Paleolog; N J Horwood; F M Brennan; B M J Foxwell
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 2.  Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.

Authors:  B Foxwell; E Andreakos; F Brennan; M Feldmann; C Smith; M Conron
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Evidence for a DC-specific inhibitory mechanism that depends on MyD88 and SIGIRR.

Authors:  S K Drexler; J Wales; E Andreakos; P Kong; A Davis; C Garlanda; A Mantovani; T Hussell; M Feldmann; B M J Foxwell
Journal:  Scand J Immunol       Date:  2010-06       Impact factor: 3.487

4.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

5.  The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis.

Authors:  Sandra M Sacre; Evangelos Andreakos; Serafim Kiriakidis; Parisa Amjadi; Anna Lundberg; Grey Giddins; Marc Feldmann; Fionula Brennan; Brian M Foxwell
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

6.  TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Authors:  Anne Gingery; Elizabeth W Bradley; Larry Pederson; Ming Ruan; Nikki J Horwood; Merry Jo Oursler
Journal:  Exp Cell Res       Date:  2008-06-13       Impact factor: 3.905

Review 7.  NF-κB inducing kinase: a key regulator in the immune system and in cancer.

Authors:  Yee Mon Thu; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-03       Impact factor: 7.638

8.  NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis.

Authors:  Kunihiko Aya; Muhammad Alhawagri; Amanda Hagen-Stapleton; Hideki Kitaura; Osami Kanagawa; Deborah Veis Novack
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

Review 9.  Nf-kappa B, chemokine gene transcription and tumour growth.

Authors:  Ann Richmond
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

10.  B-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.

Authors:  Sumit Bhattacharyya; Alip Borthakur; Sangeeta Tyagi; Ravinder Gill; Mei Ling Chen; Pradeep K Dudeja; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2009-11-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.